Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTATATE in Metastatic Breast Cancer
NCT04529044Phase 2Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in breast cancer, sponsored by OHSU Knight Cancer Institute. Started Jun 2026; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04529044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04529044.